IGM Biosciences Statistics
Total Valuation
IGM Biosciences has a market cap or net worth of $74.12 million. The enterprise value is -$64.48 million.
Important Dates
The last earnings date was Thursday, March 6, 2025, after market close.
Earnings Date | Mar 6, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
IGM Biosciences has 59.78 million shares outstanding. The number of shares has increased by 15.68% in one year.
Current Share Class | 34.39M |
Shares Outstanding | 59.78M |
Shares Change (YoY) | +15.68% |
Shares Change (QoQ) | +0.32% |
Owned by Insiders (%) | 2.50% |
Owned by Institutions (%) | 11.10% |
Float | 10.68M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 28.01 |
Forward PS | 6.21 |
PB Ratio | 1.54 |
P/TBV Ratio | 1.54 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.14, with a Debt / Equity ratio of 0.94.
Current Ratio | 5.14 |
Quick Ratio | 4.90 |
Debt / Equity | 0.94 |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -155.76% and return on invested capital (ROIC) is -72.02%.
Return on Equity (ROE) | -155.76% |
Return on Assets (ROA) | -35.23% |
Return on Invested Capital (ROIC) | -72.02% |
Return on Capital Employed (ROCE) | -85.16% |
Revenue Per Employee | $17,980 |
Profits Per Employee | -$1.31M |
Employee Count | 149 |
Asset Turnover | 0.01 |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -86.62% in the last 52 weeks. The beta is 0.36, so IGM Biosciences's price volatility has been lower than the market average.
Beta (5Y) | 0.36 |
52-Week Price Change | -86.62% |
50-Day Moving Average | 1.41 |
200-Day Moving Average | 8.33 |
Relative Strength Index (RSI) | 37.42 |
Average Volume (20 Days) | 200,216 |
Short Selling Information
The latest short interest is 928,250, so 1.55% of the outstanding shares have been sold short.
Short Interest | 928,250 |
Short Previous Month | 1.15M |
Short % of Shares Out | 1.55% |
Short % of Float | 8.70% |
Short Ratio (days to cover) | 3.98 |
Income Statement
In the last 12 months, IGM Biosciences had revenue of $2.68 million and -$195.80 million in losses. Loss per share was -$3.24.
Revenue | 2.68M |
Gross Profit | -152.51M |
Operating Income | -194.22M |
Pretax Income | -236.33M |
Net Income | -195.80M |
EBITDA | -185.11M |
EBIT | -194.22M |
Loss Per Share | -$3.24 |
Full Income Statement Balance Sheet
The company has $183.79 million in cash and $45.19 million in debt, giving a net cash position of $138.60 million or $2.32 per share.
Cash & Cash Equivalents | 183.79M |
Total Debt | 45.19M |
Net Cash | 138.60M |
Net Cash Per Share | $2.32 |
Equity (Book Value) | 48.17M |
Book Value Per Share | 0.81 |
Working Capital | 155.98M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$153.00 million and capital expenditures -$5.85 million, giving a free cash flow of -$158.85 million.
Operating Cash Flow | -153.00M |
Capital Expenditures | -5.85M |
Free Cash Flow | -158.85M |
FCF Per Share | -$2.66 |
Full Cash Flow Statement Margins
Gross Margin | n/a |
Operating Margin | -7,249.61% |
Pretax Margin | -7,308.51% |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
IGM Biosciences does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -15.68% |
Shareholder Yield | -15.68% |
Earnings Yield | -264.15% |
FCF Yield | -214.31% |
Analyst Forecast
The average price target for IGM Biosciences is $6.14, which is 395.16% higher than the current price. The consensus rating is "Hold".
Price Target | $6.14 |
Price Target Difference | 395.16% |
Analyst Consensus | Hold |
Analyst Count | 8 |
Revenue Growth Forecast (5Y) | 53.97% |
EPS Growth Forecast (5Y) | -23.89% |
Stock Forecasts Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
IGM Biosciences has an Altman Z-Score of -5.31 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | -5.31 |
Piotroski F-Score | 3 |